Pharming Group (NASDAQ:PHAR - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $70.36 million for the quarter. Pharming Group has set its FY 2025 guidance at EPS.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million during the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Pharming Group Stock Performance
PHAR traded up $0.07 during trading on Friday, hitting $10.26. 13,045 shares of the company traded hands, compared to its average volume of 4,163. The firm has a market cap of $702.91 million, a P/E ratio of -51.30 and a beta of 0.02. The stock's fifty day moving average is $10.69 and its 200 day moving average is $9.44. The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.39. Pharming Group has a one year low of $6.65 and a one year high of $12.61.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
